Accelerated Development of a COVID-19 Lateral Flow Test in an Academic Setting: Lessons Learned
Accounts of Chemical Research · 2024
DOI: 10.1021/acs.accounts.4c00075 ↗Kurz gefasst
Fachartikel in der Zeitschrift Accounts of Chemical Research, 2024. Verfasst von Katerina Kourentzi und 3 weiteren Autor:innen. Beteiligte Einrichtung: William A. Brookshire Department of Chemical and Biomolecular Engineering, University of Houston, Houston, Texas 77004, United States. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, NIBIB NIH HHS, Point Of Care Technology Research Network.
Abstract (Originalsprache)
The COVID-19 pandemic further demonstrated the need for usable, reliable, and cost-effective point-of-care diagnostics that can be broadly deployed, ideally for self-testing at home. Antigen tests using more-detectable reporter labels (usually at the cost of reader complexity) achieve better diagnostic sensitivity, supporting the value of higher-analytical-sensitivity reporter technologies in lateral flow.We developed a new approach to simple, inexpensive lateral flow assays (LFAs) of great sensitivity, based on the glow stick peroxyoxalate chemistry widely used in emergency settings and in children's toys. At the peak of the COVID-19 pandemic, we had the opportunity to participate in the pandemic-driven NIH Rapid Acceleration of Diagnostics (RADx) initiative aiming to develop a deployable lateral flow diagnostic for SARS-CoV-2 nucleoprotein based on our novel glow stick-inspired light-emitting reporter technology. During this project, we screened more than 250 antibody pairs for analytical sensitivity and specificity directly in LFA format, using recombinant nucleoprotein and then gamma-irradiated virions spiked into negative nasal swab extracts. Membranes and other LFA materials and swabs and extraction reagent components also were screened and selected. Optimization of conjugate preparation and spraying as well as pretreatment/conditioning of the sample pad led to the final optimized LFA strip. Technology development also included optimization of excitation liquid enclosed in disposable droppers, design of a custom cartridge and smartphone-based reader, and app development, even a prototype reader usable with any mobile phone. Excellent preclinical performance was first demonstrated with contrived samples and then with leftover clinical samples. Moving beyond traditional academic focus areas, we were able to establish a quality management system (QMS), produce large numbers of customized LFA cassettes by contract injection molding, build in-house facilities to assemble and store thousands of complete tests for verification and validation and usability studies, and source kitting/packaging services and quality standard reagents and build partnerships for clinical translation, regulatory guidance, scale up, and market deployment. We were not able to bring this early stage technology to the point of commercialization within the limited time and resources available, but we did achieve strong proof-of-concept and advance translational aspects of the platform including initial high-performance LFAs, reading by the iPhone app using only a $2 plastic dark box with no lens, and convenient, usable excitation liquid packaging in droppers manufacturable in very large numbers.In this Account, we aim to provide a concise overview of our 18-month sprint toward the practical development of a deployable antigen lateral flow assay under pandemic conditions and the challenges and successes experienced by our team. We highlight what it takes to coach a technically savvy but commercially inexperienced academic team through the accelerated translation of an early stage technology into a useful product. Finally, we provide a guided tutorial and workflow to empower others interested in the rapid development of translatable LFAs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- William A. Brookshire Department of Chemical and Biomolecular Engineering, University of Houston, Houston, Texas 77004, United States.
- Department of Biomedical Engineering, University of Houston, Houston, Texas 77004, United States.
- Department of Biology and Biochemistry, University of Houston, Houston, Texas 77004, United States.
- Escuela de Medicina y Ciencias de Salud, Tecnológico de Monterrey, 64849 Monterrey, Nuevo León, México.
ORCID-Profile: Katerina Kourentzi, Richard C Willson
Förderung
- NIAID NIH HHS
- NIBIB NIH HHS
- Point Of Care Technology Research Network
- National Institute of Allergy and Infectious Diseases
- University of Houston
- Consortia for Improving Medicine with Innovation and Technology
- Tondu Corporation
Zitieren
APA
Kourentzi, K., Brosamer, K., Vu, B., & Willson, R. C. (2024). Accelerated Development of a COVID-19 Lateral Flow Test in an Academic Setting: Lessons Learned. Accounts of Chemical Research. https://doi.org/10.1021/acs.accounts.4c00075
Vancouver
Kourentzi K, Brosamer K, Vu B, Willson RC. Accelerated Development of a COVID-19 Lateral Flow Test in an Academic Setting: Lessons Learned. Accounts of Chemical Research. 2024. doi:10.1021/acs.accounts.4c00075
BibTeX
@article{Kourentzi2024,
author = {Kourentzi, Katerina and Brosamer, Kristen and Vu, Binh and Willson, Richard C},
title = {Accelerated Development of a COVID-19 Lateral Flow Test in an Academic Setting: Lessons Learned},
journal = {Accounts of Chemical Research},
year = {2024},
doi = {10.1021/acs.accounts.4c00075}
}
EUVIMED